Antibiotic Resistance and Antibiotic Technologies: Global Markets
December 29, 2009
Wellesley, Mass. – According to a new technical market research report, ANTIBIOTIC RESISTANCE AND ANTIBIOTIC TECHNOLOGIES: GLOBAL MARKETS (PHM025B) from BCC Research (www.bccresearch.com), the value of current antibiotics and new products in the global market is an estimated $41.5 billion in 2009, but is expected to increase to $65.5 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 9.6%.
The largest segment of the market, antibiotic drugs, is projected to grow at a CAGR of 5.9% to reach $50 billion in 2014. Its value is estimated at $37.6 billion in 2009.
Bacterial vaccines, the other segment of the market, is estimated at $3.9 billion in 2009, and is expected to increase at a 5-year CAGR of 31.6% to reach $15.5 billion in 2014.
SUMMARY FIGURE
GLOBAL ANTIBIOTICS MARKET BY PRODUCT CLASSES, 2009
(%)
To Contact us, click here 
Source: BCC Research
Antibiotic resistance is a major health crisis throughout the world that requires an intensely focused action plan. Although resistance cannot be prevented, the problem is exacerbated by the fact that the pipeline targeting it is very lean, as the field was neglected by the industry for a long time.
The antibiotics sector is witnessing a new wave of interest in terms of investment, which is leading to innovation that was absent for more than two decades. The bacterial vaccines sector is expected to show particularly commendable growth trends during the 2009-2014 forecast period.
Regulatory trends emerging in various markets are expected to play key roles in the market growth. Because the best way to contain the resistance problem is to restrict the use of these products, it is expected to have a negative effect on the sector’s market growth. This is especially true for the established antibiotic classes that are facing serious resistance issues. Thus, the use of new classes of antibiotics will be encouraged, which will drive market growth.
This report is valuable reading for investors, policy makers, and industry participants.
Analyses have been conducted to help strategy developers and decision makers within pharmaceutical companies and government bodies. The detailed analyses of the regulatory factors that play major roles in deciding the industry trends are especially useful for legislators involved in government policy development programs.
Antibiotic Resistance and Antibiotic Technologies: Global Markets( PHM025B )
Publish Date: Nov 2009
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
Antibiotic Resistance and Antibiotic Technologies: Global Markets
Customize This Report More in Pharmaceuticals
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum
- Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030
- AI in Clinical Trials Poised for Rapid Growth with a 22.6% CAGR Forecast
Reports from Pharmaceuticals
Recent News
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand